CA2752009C - Orosoluble and/or effervescent compositions containing at least a salt of s-adenosyl methionine (same) - Google Patents
Orosoluble and/or effervescent compositions containing at least a salt of s-adenosyl methionine (same) Download PDFInfo
- Publication number
- CA2752009C CA2752009C CA2752009A CA2752009A CA2752009C CA 2752009 C CA2752009 C CA 2752009C CA 2752009 A CA2752009 A CA 2752009A CA 2752009 A CA2752009 A CA 2752009A CA 2752009 C CA2752009 C CA 2752009C
- Authority
- CA
- Canada
- Prior art keywords
- same
- composition according
- orosoluble
- salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001570 ademetionine Drugs 0.000 title claims abstract description 113
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 title claims abstract description 89
- 150000003839 salts Chemical class 0.000 title claims abstract description 28
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 208000019423 liver disease Diseases 0.000 claims abstract description 10
- 235000019629 palatability Nutrition 0.000 claims abstract description 9
- 241000282414 Homo sapiens Species 0.000 claims abstract description 6
- 235000005911 diet Nutrition 0.000 claims abstract description 3
- 230000000378 dietary effect Effects 0.000 claims abstract 2
- 239000002417 nutraceutical Substances 0.000 claims abstract 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 45
- -1 flavolignan Substances 0.000 claims description 30
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 17
- VERAMNDAEAQRGS-UHFFFAOYSA-N butane-1,4-disulfonic acid Chemical compound OS(=O)(=O)CCCCS(O)(=O)=O VERAMNDAEAQRGS-UHFFFAOYSA-N 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 5
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 5
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 5
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 5
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 5
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 5
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 5
- 240000000171 Crataegus monogyna Species 0.000 claims description 5
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 5
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 5
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 5
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 5
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 5
- 244000179684 Passiflora quadrangularis Species 0.000 claims description 5
- 235000011266 Passiflora quadrangularis Nutrition 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 235000002949 phytic acid Nutrition 0.000 claims description 5
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229960004308 acetylcysteine Drugs 0.000 claims description 4
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 4
- 235000017803 cinnamon Nutrition 0.000 claims description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 235000013311 vegetables Nutrition 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
- 240000002319 Citrus sinensis Species 0.000 claims description 3
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 3
- 240000006927 Foeniculum vulgare Species 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
- 241000546188 Hypericum Species 0.000 claims description 3
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 208000021642 Muscular disease Diseases 0.000 claims description 3
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 3
- 240000002657 Thymus vulgaris Species 0.000 claims description 3
- 244000126014 Valeriana officinalis Species 0.000 claims description 3
- 235000013832 Valeriana officinalis Nutrition 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims description 3
- 230000007872 intrahepatic cholestasis Effects 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 239000005445 natural material Substances 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- 229960004245 silymarin Drugs 0.000 claims description 3
- 235000017700 silymarin Nutrition 0.000 claims description 3
- 230000007863 steatosis Effects 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 239000001585 thymus vulgaris Substances 0.000 claims description 3
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 3
- 229960001661 ursodiol Drugs 0.000 claims description 3
- 235000016788 valerian Nutrition 0.000 claims description 3
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims description 2
- 244000291564 Allium cepa Species 0.000 claims description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims description 2
- 240000002234 Allium sativum Species 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 2
- 108010004032 Bromelains Proteins 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 2
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 241000378467 Melaleuca Species 0.000 claims description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 claims description 2
- 244000057717 Streptococcus lactis Species 0.000 claims description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 229960005261 aspartic acid Drugs 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- 235000019835 bromelain Nutrition 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229950006137 dexfosfoserine Drugs 0.000 claims description 2
- 108700003601 dimethylglycine Proteins 0.000 claims description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 2
- 235000004611 garlic Nutrition 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002743 glutamine Drugs 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 229960003208 levomefolic acid Drugs 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 235000012661 lycopene Nutrition 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 2
- 229960003987 melatonin Drugs 0.000 claims description 2
- 229940016409 methylsulfonylmethane Drugs 0.000 claims description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 2
- 235000005493 rutin Nutrition 0.000 claims description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 2
- 229960004555 rutoside Drugs 0.000 claims description 2
- 229940043175 silybin Drugs 0.000 claims description 2
- 235000014899 silybin Nutrition 0.000 claims description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 229940026510 theanine Drugs 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- GIOCILWWMFZESP-UHFFFAOYSA-N 2-hydroxyethyl butanoate Chemical compound CCCC(=O)OCCO GIOCILWWMFZESP-UHFFFAOYSA-N 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims 1
- 241001529735 Melissa Species 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229960004999 lycopene Drugs 0.000 claims 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims 1
- 239000001751 lycopene Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 abstract description 57
- 239000008187 granular material Substances 0.000 abstract description 12
- 239000002775 capsule Substances 0.000 abstract description 8
- 235000002639 sodium chloride Nutrition 0.000 description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 239000000796 flavoring agent Substances 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 238000005303 weighing Methods 0.000 description 16
- 235000019634 flavors Nutrition 0.000 description 13
- 230000036470 plasma concentration Effects 0.000 description 13
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000811 xylitol Substances 0.000 description 9
- 235000010447 xylitol Nutrition 0.000 description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 9
- 229960002675 xylitol Drugs 0.000 description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 235000021355 Stearic acid Nutrition 0.000 description 8
- 239000004376 Sucralose Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 8
- 239000008117 stearic acid Substances 0.000 description 8
- 235000019408 sucralose Nutrition 0.000 description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 8
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 6
- 238000010579 first pass effect Methods 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 235000015497 potassium bicarbonate Nutrition 0.000 description 5
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 5
- 239000011736 potassium bicarbonate Substances 0.000 description 5
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 5
- 235000002906 tartaric acid Nutrition 0.000 description 5
- 239000011975 tartaric acid Substances 0.000 description 5
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 4
- 239000000619 acesulfame-K Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 229960000367 inositol Drugs 0.000 description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 4
- 229960003136 leucine Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 4
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000009470 Theobroma cacao Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000001361 adipic acid Substances 0.000 description 3
- 235000011037 adipic acid Nutrition 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 229940093797 bioflavonoids Drugs 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007938 effervescent tablet Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 3
- 235000013923 monosodium glutamate Nutrition 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013082 Discomfort Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 244000078639 Mentha spicata Species 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 229940011037 anethole Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 description 2
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000008368 mint flavor Substances 0.000 description 2
- 239000004223 monosodium glutamate Substances 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 239000000561 aggregant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- ZFAVADMJZHASIM-UHFFFAOYSA-N hydroxymethyl butanoate Chemical compound CCCC(=O)OCO ZFAVADMJZHASIM-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002664 lycopenes Chemical class 0.000 description 1
- 229940009048 magnesium oxide 40 mg Drugs 0.000 description 1
- 229940033206 melatonin 1 mg Drugs 0.000 description 1
- 239000001098 melissa officinalis l. leaf oil Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940112824 paste Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- PKIDNTKRVKSLDB-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;hydrate Chemical compound O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PKIDNTKRVKSLDB-UHFFFAOYSA-K 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 229940115522 tryptophan 100 mg Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940118573 xylitol 500 mg Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Abstract
The present invention refers to pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent compo-sitions for oral use containing at least a salt of S-adenosyl methionine (SAMe), combined with physiologically acceptable excipi-ents and optionally additional active ingredients. In particular the invention refers to compositions with high palatability formulat-ed in tablet, capsule or granules. The present invention also refers to the use of at least a salt of SAMe combined with physiologi-cally acceptable excipients and optionally further active ingredients for treating, human or veterinarian, neuropsychiatric, osteoar-ticular or hepatic diseases.
Description
Orosoluble and/or effervescent compositions containing at least a salt of S-adenosyl methionine (SAMe) S-adenosyl methionine (SAMe) is an important physiological molecule discovered in 1952 which is formed in the body from the combination of the methionine essential amino acid with adenosine triphosphate (ATP), in a highly demanding reaction as far as energy consumption is concerned, controlled by the SAMe synthetase enzyme.
The main natural source of SAMe for human beings is through intake of food with high protein content of its methionine precursor. It is calculated that a person under normoprotein diet averagely ingests about 1 gram of methionine to be converted into SAMe per day.
The half-life of SAMe in the liver is very short (about 5 minutes) which demonstrates the avidity of the organ for this molecule.
A good and balanced nutrition represents the key factor to supply the body with the required daily bioavailability of SAMe which may be assumed to be about mg and plasma levels between 20 and 50 mg/ml (Bottiglieri T.:SAMe: from the bench to the beside-molecular basis of a pleiotropic molecule. Am. J. Clin.
Nutr., 2002, 76:1151 S-1157S).
The most known deficiency conditions are for example represented by senescence wherein there occurs a drop of SAMe exceeding 50%, neurological diseases which involve the emotional sphere (depression syndromes in general) and cognitive sphere (dementia), both acute and chronic hepatic disorders (alcoholic steatosis, acute and chronic hepatitis, alcoholic and post-viral cirrhosis, intrahepatic cholestasis) and by degenerative skeletal-muscular diseases distinguished by mobility disorders (osteoarthrosis) (Grazi S., Costa M. :SAMe The safe and natural way to combat depression and relieve the pain of osteoarthiritis. Prima Health, Rocklin, CA, 1999).
The main natural source of SAMe for human beings is through intake of food with high protein content of its methionine precursor. It is calculated that a person under normoprotein diet averagely ingests about 1 gram of methionine to be converted into SAMe per day.
The half-life of SAMe in the liver is very short (about 5 minutes) which demonstrates the avidity of the organ for this molecule.
A good and balanced nutrition represents the key factor to supply the body with the required daily bioavailability of SAMe which may be assumed to be about mg and plasma levels between 20 and 50 mg/ml (Bottiglieri T.:SAMe: from the bench to the beside-molecular basis of a pleiotropic molecule. Am. J. Clin.
Nutr., 2002, 76:1151 S-1157S).
The most known deficiency conditions are for example represented by senescence wherein there occurs a drop of SAMe exceeding 50%, neurological diseases which involve the emotional sphere (depression syndromes in general) and cognitive sphere (dementia), both acute and chronic hepatic disorders (alcoholic steatosis, acute and chronic hepatitis, alcoholic and post-viral cirrhosis, intrahepatic cholestasis) and by degenerative skeletal-muscular diseases distinguished by mobility disorders (osteoarthrosis) (Grazi S., Costa M. :SAMe The safe and natural way to combat depression and relieve the pain of osteoarthiritis. Prima Health, Rocklin, CA, 1999).
2 Supplementation with exogenous SAMe follows the same metabolic path as the natural molecule derived from nutritional methionine.
The idea of administering exogenous SAMe to patients was pursued since the discovery of the molecule in the fifties, but it was only after the second half of the seventies that it was put into practice with the introduction into the pharmaceutical market of the first preparations, administered parenterally (both endovenous and intramuscular) or orally (swallowable, either gastro-protected or gastro-resistant tablets) of salts of SAMe (such as for example tosylate, butanedisulfonate or phytate), stable at room temperature.
In particular, United States patents US3954726 and US4057672 describe relatively stable salts of S-adenosyl methionine, i.e. up to 25 C and 45 C, respectively. Furthermore, the United States patent US4465672 describes stable salts of S-adenosyl methionine with 5 moles of a sulfonic acid with pK lower than 2.5.
In brief, non-salified SAMe is very unstable at temperatures above 0 C.
Alongside thermolability, the second important factor of degradation of the molecule is represented by its hygroscopicity which can be bypassed by preserving the thermostable salts of SAMe in special protection casings or freeze-drying the salt under vacuum and putting it into a vial.
The availability of stable pharmaceutical preparations based on salts of SAMe allowed carrying out several clinical trials in various therapeutic uses such as depression syndromes, dementia, hepatopathies, osteoarthrosis, fibromyalgia, with the observation of proven clinical effectiveness combined with high tolerance to the molecule (Friedel HA, Goa KL, Benfield P.:SAMe : A review of its therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs, 1989, 38:389-416).
The idea of administering exogenous SAMe to patients was pursued since the discovery of the molecule in the fifties, but it was only after the second half of the seventies that it was put into practice with the introduction into the pharmaceutical market of the first preparations, administered parenterally (both endovenous and intramuscular) or orally (swallowable, either gastro-protected or gastro-resistant tablets) of salts of SAMe (such as for example tosylate, butanedisulfonate or phytate), stable at room temperature.
In particular, United States patents US3954726 and US4057672 describe relatively stable salts of S-adenosyl methionine, i.e. up to 25 C and 45 C, respectively. Furthermore, the United States patent US4465672 describes stable salts of S-adenosyl methionine with 5 moles of a sulfonic acid with pK lower than 2.5.
In brief, non-salified SAMe is very unstable at temperatures above 0 C.
Alongside thermolability, the second important factor of degradation of the molecule is represented by its hygroscopicity which can be bypassed by preserving the thermostable salts of SAMe in special protection casings or freeze-drying the salt under vacuum and putting it into a vial.
The availability of stable pharmaceutical preparations based on salts of SAMe allowed carrying out several clinical trials in various therapeutic uses such as depression syndromes, dementia, hepatopathies, osteoarthrosis, fibromyalgia, with the observation of proven clinical effectiveness combined with high tolerance to the molecule (Friedel HA, Goa KL, Benfield P.:SAMe : A review of its therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs, 1989, 38:389-416).
3 After being first used in Italy, the use of SAMe in the pharmaceutical industry spread into other countries such as Spain, Germany, Russia, and China in the 80s-90s.
Lastly, starting from 1999 SAMe, salified with tosylate or butanedisulfonate, was introduced in the USA as a food supplement still in form of gastro-protected swallowable tablets dosed at 200 and 400 mg of active ingredient.
While parenteral administration (i.e. endovenous or intramuscular) of exogenous SAMe guarantees high levels of plasma bioavailability (corresponding to about 90-100% of the administered dose), oral intake of SAMe through swallowable gastro-protected tablets only produces low plasma levels of the non-modified molecule i.e. < 5-10% of the administered dose.
This considerable bioavailability difference derives from the high presystemic metabolism at the hepatic level of the SAMe taken orally in gastro-protected form (i.e. gastro-resistant, capable of passing unaltered through the gastric environment and dissolving solely at the intestinal level, tributary of the portal vein).
As a matter of fact, it is known that oral intake of SAMe, radiolabeled on the carbon of the methyl group, leads to an intensive hepatic metabolism assessable at about 60% of the administered radioactivity (Giulidori P. et al.-Metabolism of exogenous SAMe in humans and its significance in the therapeutic use of the drug. Proceedings of the Workshop "Methionine Metabolism: Molecular Mechanisms and Clinical Implications". Madrid, Spain, Jarpyo Editores, 1998:159-163).
The high presystemic metabolism in the liver depends on the selective absorption of the SAMe at enteric level, due to the gastro-protected formulation thereof suitable to facilitate direct transfer thereof to the liver through the dominating enterohepatic portal venous system.
Lastly, starting from 1999 SAMe, salified with tosylate or butanedisulfonate, was introduced in the USA as a food supplement still in form of gastro-protected swallowable tablets dosed at 200 and 400 mg of active ingredient.
While parenteral administration (i.e. endovenous or intramuscular) of exogenous SAMe guarantees high levels of plasma bioavailability (corresponding to about 90-100% of the administered dose), oral intake of SAMe through swallowable gastro-protected tablets only produces low plasma levels of the non-modified molecule i.e. < 5-10% of the administered dose.
This considerable bioavailability difference derives from the high presystemic metabolism at the hepatic level of the SAMe taken orally in gastro-protected form (i.e. gastro-resistant, capable of passing unaltered through the gastric environment and dissolving solely at the intestinal level, tributary of the portal vein).
As a matter of fact, it is known that oral intake of SAMe, radiolabeled on the carbon of the methyl group, leads to an intensive hepatic metabolism assessable at about 60% of the administered radioactivity (Giulidori P. et al.-Metabolism of exogenous SAMe in humans and its significance in the therapeutic use of the drug. Proceedings of the Workshop "Methionine Metabolism: Molecular Mechanisms and Clinical Implications". Madrid, Spain, Jarpyo Editores, 1998:159-163).
The high presystemic metabolism in the liver depends on the selective absorption of the SAMe at enteric level, due to the gastro-protected formulation thereof suitable to facilitate direct transfer thereof to the liver through the dominating enterohepatic portal venous system.
4 PCT/IB2010/050087 The systemic bioavailability levels of the molecule are drastically lowered by the metabolic avidity of the liver for SAMe.
Whereas this high presystemic metabolism of the SAMe is not prejudicial in subjects suffering from hepatic diseases, on the contrary it strongly jeopardises subjects who take orally the molecule to obtain clinical benefit related to other morbid diseases, in particular subjects suffering from depression syndromes or from osteoarthrosis, in which case molecular tropism of the extrahepatic SAMe is required.
It has been demonstrated in depressed subjects that the small plasma amount of SAMe that escapes the hepatic uptake is still capable of overcoming the obstacle of the hematoencephalic barrier and accumulating in small amounts in the cephalorachidian liquid. Regarding patients suffering from osteoarthrosis, SAMe is also capable of concentrating in the synovial fluid of the joints.
Thus, though penalised by the extensive first pass effect, the gastro-protected oral SAMe reaches the elected therapeutic sites in very little amounts.
Therefore, there is the need to increase the systemic bioavailability of the SAMe and/or its salts, when administered orally, so as to make it more suitable for treating extrahepatic diseases, for example, those regarding the central nervous system or the osteoarticular system.
Now, it has been surprisingly found that it is possible to overcome the obstacle of the hepatic presystemic metabolism of the salts of SAMe, related to the current swallowable and gastro-resistant oral formulations, through formulation in specific non-gastro-resistant orosoluble and/or effervescent compositions.
Preferably, said orosoluble and/or effervescent compositions are characterised in that they have a high palatability, which guarantees easy oral administration thereof.
Through orosoluble and/or effervescent formulations, the salts of SAMe are administered and absorbed directly in the oral cavity generating a much quicker absorption and a considerably higher bioavailability with respect to the current method of administration by means of gastro-resistant tablets, considering the same dose of active ingredient.
A similar technical effect is interpretable in the light of the fact that the oral haematic system drains in the superior vena cava avoiding the portal venous system responsible for the known first pass effect, thus improving the systemic bioavailability.
Thus, the present invention refers to orosoluble and/or effervescent compositions for oral use containing at least a salt of SAMe combined with physiologically acceptable excipients.
The orosoluble and/or effervescent compositions of the invention are preferably characterised in that they have a high palatability which guarantees easy oral administration thereof.
Said high palatability also determines in the treated subject (human or animal) a greater period of permanence of the composition in the oral cavity, and an ensuing lower impulse to swallow, which contributes to improve the rate of absorption and the bioavailability of the active ingredient.
According to the present invention the term "SAMe" is used to indicate both the racemic mixture and the single diastereoisomers (RS)-(+)-S-adenosyl-L-methionine [(RS)-(.+)-SAMe)] and (SS)-(+)-S-adenosyl-L-methionine [(SS)-(+)-SAMe)], even in mixtures different from the racemic one.
According to the present invention the salts of SAMe are preferably selected from among tosylate (para-toluenesulfonate), butanedisulfonate, phytate or a mixture thereof. Said at least a salt of SAMe is comprised in the compositions according to the invention in an amount ranging from 5 to 70% by weight, preferably from to 50 % by weight, with respect to the weight of the composition.
According to the invention, said percentage ranges refer to the total amount of the salt of SAMe, or to the total amount of the salts of SAMe in the mixture, contained in the composition.
The orosoluble and/or effervescent compositions of the invention may thus be formulated in form of tablet, capsule and/or granules, preferably in form of orosoluble and/or effervescent tablet. The compositions of the invention may also be formulated in form of sublingual tablet.
According to the invention, the term "sublingual" refers to compositions which must specifically be placed under the tongue in order to dissolve and release the active ingredient.
According to the invention the term "orosoluble" refers to a composition capable of immediately dissolving and releasing the active ingredient contained therein upon contact with the oral mucosa. In this manner, the active ingredient may be directly absorbed in the oral mucosa, thus bypassing the hepatic system.
According to the invention the term orosoluble is therefore preferably used to indicate compositions to be introduced into the oral cavity.
In order to obtain the orosoluble form, the compositions of the invention are preferably formulated using the following classes of excipients: diluents, aggregants or binding agents, lubricants, glidants, disaggregants, solubilisers, sweeteners, flavouring agents and/or pH adjusters.
More preferably, the orosoluble compositions according to the invention are formulated with light magnesium oxide, magnesium hydroxide, alginic acid, stearic acid, hydrogenated vegetable oils (palm, oleic, behenic), cocoa butter, cocoa paste, xylitol, maltitol, sorbitol, mannitol, sucralose, acesulfame K, cyclamate, aspartame, sucrose, neohesperidine, fructose, dextrose, maltose, spray dried malt, sodium aspartate, maltodextrines, inositol, inulin, chitosan, beer yeast or a mixture thereof.
In particular, in order to obtain the orosoluble form, said excipients are present in the compositions of the invention in an amount ranging from 20% to 95% by weight, with respect to the total weight of the formulation.
According to the invention, the term "effervescent" instead refers to compositions capable of developing carbon dioxide when at contact with water and/or with the buccal environment, in the presence of saliva and they are divided into:
= A: slightly effervescent orosoluble tablets. Thus capable of developing slight effervescence capable of guaranteeing high palatability associated to a dissolution time within 10 minutes.
= B: classic effervescent tablets. To be dissolved in water and to be taken at small sips.
In order to obtain the effervescent form, the compositions of the invention are preferably formulated using di- and tri-carboxylic acids or a mixture thereof.
More preferably, the effervescent compositions according to the invention are formulated with dihydrate and monohydrate sodium citrate, sodium carbonate, disodium carbonate, potassium bicarbonate, citric acid, tartaric acid, adipic acid, monosodium phosphate, alginic acid, magnesium hydroxycarbonate or a mixture thereof.
In particular, in order to obtain the effervescent form, said excipients are present in the compositions of the invention in an amount ranging from 30% to 95% by weight, with respect to the total weight of the formulation.
The compositions of the invention may therefore be formulated in orosoluble form, effervescent form or a combined orosoluble and effervescent form.
The term "high palatability" according to the invention refers to compositions having a particularly pleasant taste that can be easily administered orally regardless of the fact that the active ingredients contained therein may have an unpleasant, bitter and/or sour taste.
Further useful excipients according to the invention are selected from among sodium-, calcium-, magnesium-, potassium-citrate, sodium-, calcium-, magnesium-, potassium-phosphate, light magnesium oxide, magnesium hydroxide, magnesium hydroxycarbonate, sodium carbonate, sodium chloride, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, adipic acid, citric acid, tartaric acid, alginic acid, stearic acid and its salts, oleic acid, 1-leucine, glycerol behenate, hydroxypropylmethylcellulose, hydrogenated vegetable oils (such as for example palm oil), palm butter, cocoa butter, cocoa paste, cocoa powder, xylitol, maltitol, sorbitol, mannitol, sucralose, acesulfame K, sodium cyclamate, aspartame, sucrose, erythritol, citrus extract, fructose, dextrose, maltose, spray dried malt, sodium aspartate, neohesperidine, maltodextrines, inositol, inulin, beer yeast, silica gel, vegetable fibres (such as for example pea fibre), chitosan, flavouring agents (essential oils, powders and the like): mint (peppermint, spearmint, sweet mint), badian anethole, vanilla, sage, liver, sodium glutamate, fish meal, chicken, grapefruit, peach, lime or a mixture thereof.
The compositions according to the present invention may also contain at least a further active ingredient in combination with said at least a salt of SAMe, maintaining the high palatability of the compositions. Said further active ingredient is preferably selected from among vitamins, amino acids, glycosaminoglycans, flavolignans, hormones, natural substances of animal or vegetable origin, enzymes,-polysaccharides, probiotics or a mixture thereof.
In particular, said further active ingredient may be selected from among vitamins of group B such as, for example, vitamin B6, vitamin B12, vitamin B9 (folic acid), methylfolate, vitamin C; magnesium salts; taurine, tryptophan, reduced glutathione, n-acetylcysteine, tyrosine; hyaluronic acid, silymarin, silybin, theanine, melatonin, bromelain, hypericum, lipoic acid, lycopenes, bioflavonoids, rutin, valerian, glucosamine, chondroitin sulphate, chitosan, ursodeoxycholic acid, lactobacillus acidophilus, lactobacillus vulgaris, bifidum bacterium brevi, bifidum infantis, bifidum bacterium lactis, bifidum bacterium longum, lactobacillus bulgaricus, lactobacillus casei, lactobacillus plantarum, lactobacillus rhamnosus;
melissa, cinnamon, hawthorn, granadilla, fennel, dried garlic, onion, melaleuca, sweet orange, camomile, thyme (in form of essential oils, mother tinctures, retted glycerides or powders), betaine, aspartic acid, glutamine, phosphoserine, phosphatidylserine, choline, coenzyme Q10, dimethylglycine, hydroxymethylbutyrate, lactoferrin, methylsulfonylmethane, homotaurine, p-aminobenzoic acid (PABA), monacuspurpureus or a mixture thereof.
Said at least an additional active ingredient is contained in the composition of the invention in an amount ranging from 0.05% to 70%, preferably from 0.1 to 55%, with respect to the total weight of the composition.
Said amount varies depending on the characteristics of the selected additional active ingredient.
In particular, in case the additional active ingredient is one of the abovementioned vitamins of group B the dose according to the invention ranges from 0.00001 to 3%, preferably from 0.00005 to 1%, with respect to the total weight of the composition.
As mentioned above, administration of the composition according to the present invention guarantees an improved bioavailability of the drug, with respect to the compositions already available in the market; as a matter of fact, the administration of the invention allows reaching the plasma peak of the SAMe ion (maximum plasma concentration) within a period of time comprised between 1 and 2 hours from intake, preferably within about 1 and a half hours, with respect to a period of time of about 5 hours observed regarding a swallowable gastro-resistant tablet available in the market.
Said plasma peak of the invention corresponds to a plasma concentration value of the SAMe ion greater than 40-50% with respect to the base value, preferably equivalent to a value higher than 48% with respect to the base value, instead of the 1 % observed on a swallowable gastro-resistant tablet available in the market.
Thus, the present invention is also aimed at providing a method for obtaining the plasma peak of the SAMe ion within a period of time comprised between 1 and 2 hours from the intake, preferably within a period of time of about 1 and a half hours, characterized by the intake of the composition according to the present invention.
In particular, the method of the present invention determines a plasma concentration of the SAMe ion greater than 40-50% with respect to the base value, preferably greater than a value of about 48%, with respect to the base value.
The present invention is thus aimed at providing a method for increasing the plasma concentration of the SAMe ion characterized by administering the composition of the invention.
In particular, according to the method of the invention the value of the plasma concentration of the SAMe ion increases from 30 to 40% within a period of time preferably comprised between 20 and 40 minutes after administering the abovementioned composition. More preferably, the plasma concentration value of the SAMe ion increases by about 35% after about 30 minutes from the intake of the composition of the invention.
According to the method of the invention, the plasma peak of the SAMe ion (maximum plasma concentration) is attained within a period of time comprised between 1 and 2 hours, while the plasma concentration already increases considerably after a period of time comprised between 20 and 40 minutes from intake, thus guaranteeing the fast effectiveness.
Furthermore, the present invention refers to orosoluble and/or effervescent compositions containing at least a salt of SAMe combined with physiologically acceptable excipients used for treating, human or veterinarian, neuropsychiatric, osteoarticular or hepatic diseases and/or for treating disorders or discomforts deriving from the abovementioned diseases, in particular, diseases and/or disorders regarding the emotional sphere (depression syndromes in general, anxiety) and cognitive sphere (dementia), hepatic disorders both acute and chronic (alcoholic steatosis, acute and chronic hepatitis, alcoholic and post-viral cirrhosis, intrahepatic cholestasis) and degenerative skeletal-muscular diseases distinguished by mobility disorders (osteoarthrosis).
The abovementioned compositions for use in the treatment of human or veterinarian, neuropsychiatric, osteoarticular or hepatic diseases and/or disorders or discomforts deriving from the abovementioned diseases may also contain additional active ingredients. Said additional active ingredients being preferably selected from among vitamins, amino acids, glycosaminoglycans, flavolignans, hormones, natural substances of animal or vegetable origin, enzymes, polysaccharides, probiotics.
The compositions of the present invention may be prepared through a process comprising the following steps:
Scheme A (for orosoluble and/or effervescent tablets or granules and capsules):
1) Weighing the active components and excipients;
2) Mixing (mixer with rotating screw);
3) Compression;
4) Dry granulation of the obtained tablets;
Whereas this high presystemic metabolism of the SAMe is not prejudicial in subjects suffering from hepatic diseases, on the contrary it strongly jeopardises subjects who take orally the molecule to obtain clinical benefit related to other morbid diseases, in particular subjects suffering from depression syndromes or from osteoarthrosis, in which case molecular tropism of the extrahepatic SAMe is required.
It has been demonstrated in depressed subjects that the small plasma amount of SAMe that escapes the hepatic uptake is still capable of overcoming the obstacle of the hematoencephalic barrier and accumulating in small amounts in the cephalorachidian liquid. Regarding patients suffering from osteoarthrosis, SAMe is also capable of concentrating in the synovial fluid of the joints.
Thus, though penalised by the extensive first pass effect, the gastro-protected oral SAMe reaches the elected therapeutic sites in very little amounts.
Therefore, there is the need to increase the systemic bioavailability of the SAMe and/or its salts, when administered orally, so as to make it more suitable for treating extrahepatic diseases, for example, those regarding the central nervous system or the osteoarticular system.
Now, it has been surprisingly found that it is possible to overcome the obstacle of the hepatic presystemic metabolism of the salts of SAMe, related to the current swallowable and gastro-resistant oral formulations, through formulation in specific non-gastro-resistant orosoluble and/or effervescent compositions.
Preferably, said orosoluble and/or effervescent compositions are characterised in that they have a high palatability, which guarantees easy oral administration thereof.
Through orosoluble and/or effervescent formulations, the salts of SAMe are administered and absorbed directly in the oral cavity generating a much quicker absorption and a considerably higher bioavailability with respect to the current method of administration by means of gastro-resistant tablets, considering the same dose of active ingredient.
A similar technical effect is interpretable in the light of the fact that the oral haematic system drains in the superior vena cava avoiding the portal venous system responsible for the known first pass effect, thus improving the systemic bioavailability.
Thus, the present invention refers to orosoluble and/or effervescent compositions for oral use containing at least a salt of SAMe combined with physiologically acceptable excipients.
The orosoluble and/or effervescent compositions of the invention are preferably characterised in that they have a high palatability which guarantees easy oral administration thereof.
Said high palatability also determines in the treated subject (human or animal) a greater period of permanence of the composition in the oral cavity, and an ensuing lower impulse to swallow, which contributes to improve the rate of absorption and the bioavailability of the active ingredient.
According to the present invention the term "SAMe" is used to indicate both the racemic mixture and the single diastereoisomers (RS)-(+)-S-adenosyl-L-methionine [(RS)-(.+)-SAMe)] and (SS)-(+)-S-adenosyl-L-methionine [(SS)-(+)-SAMe)], even in mixtures different from the racemic one.
According to the present invention the salts of SAMe are preferably selected from among tosylate (para-toluenesulfonate), butanedisulfonate, phytate or a mixture thereof. Said at least a salt of SAMe is comprised in the compositions according to the invention in an amount ranging from 5 to 70% by weight, preferably from to 50 % by weight, with respect to the weight of the composition.
According to the invention, said percentage ranges refer to the total amount of the salt of SAMe, or to the total amount of the salts of SAMe in the mixture, contained in the composition.
The orosoluble and/or effervescent compositions of the invention may thus be formulated in form of tablet, capsule and/or granules, preferably in form of orosoluble and/or effervescent tablet. The compositions of the invention may also be formulated in form of sublingual tablet.
According to the invention, the term "sublingual" refers to compositions which must specifically be placed under the tongue in order to dissolve and release the active ingredient.
According to the invention the term "orosoluble" refers to a composition capable of immediately dissolving and releasing the active ingredient contained therein upon contact with the oral mucosa. In this manner, the active ingredient may be directly absorbed in the oral mucosa, thus bypassing the hepatic system.
According to the invention the term orosoluble is therefore preferably used to indicate compositions to be introduced into the oral cavity.
In order to obtain the orosoluble form, the compositions of the invention are preferably formulated using the following classes of excipients: diluents, aggregants or binding agents, lubricants, glidants, disaggregants, solubilisers, sweeteners, flavouring agents and/or pH adjusters.
More preferably, the orosoluble compositions according to the invention are formulated with light magnesium oxide, magnesium hydroxide, alginic acid, stearic acid, hydrogenated vegetable oils (palm, oleic, behenic), cocoa butter, cocoa paste, xylitol, maltitol, sorbitol, mannitol, sucralose, acesulfame K, cyclamate, aspartame, sucrose, neohesperidine, fructose, dextrose, maltose, spray dried malt, sodium aspartate, maltodextrines, inositol, inulin, chitosan, beer yeast or a mixture thereof.
In particular, in order to obtain the orosoluble form, said excipients are present in the compositions of the invention in an amount ranging from 20% to 95% by weight, with respect to the total weight of the formulation.
According to the invention, the term "effervescent" instead refers to compositions capable of developing carbon dioxide when at contact with water and/or with the buccal environment, in the presence of saliva and they are divided into:
= A: slightly effervescent orosoluble tablets. Thus capable of developing slight effervescence capable of guaranteeing high palatability associated to a dissolution time within 10 minutes.
= B: classic effervescent tablets. To be dissolved in water and to be taken at small sips.
In order to obtain the effervescent form, the compositions of the invention are preferably formulated using di- and tri-carboxylic acids or a mixture thereof.
More preferably, the effervescent compositions according to the invention are formulated with dihydrate and monohydrate sodium citrate, sodium carbonate, disodium carbonate, potassium bicarbonate, citric acid, tartaric acid, adipic acid, monosodium phosphate, alginic acid, magnesium hydroxycarbonate or a mixture thereof.
In particular, in order to obtain the effervescent form, said excipients are present in the compositions of the invention in an amount ranging from 30% to 95% by weight, with respect to the total weight of the formulation.
The compositions of the invention may therefore be formulated in orosoluble form, effervescent form or a combined orosoluble and effervescent form.
The term "high palatability" according to the invention refers to compositions having a particularly pleasant taste that can be easily administered orally regardless of the fact that the active ingredients contained therein may have an unpleasant, bitter and/or sour taste.
Further useful excipients according to the invention are selected from among sodium-, calcium-, magnesium-, potassium-citrate, sodium-, calcium-, magnesium-, potassium-phosphate, light magnesium oxide, magnesium hydroxide, magnesium hydroxycarbonate, sodium carbonate, sodium chloride, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, adipic acid, citric acid, tartaric acid, alginic acid, stearic acid and its salts, oleic acid, 1-leucine, glycerol behenate, hydroxypropylmethylcellulose, hydrogenated vegetable oils (such as for example palm oil), palm butter, cocoa butter, cocoa paste, cocoa powder, xylitol, maltitol, sorbitol, mannitol, sucralose, acesulfame K, sodium cyclamate, aspartame, sucrose, erythritol, citrus extract, fructose, dextrose, maltose, spray dried malt, sodium aspartate, neohesperidine, maltodextrines, inositol, inulin, beer yeast, silica gel, vegetable fibres (such as for example pea fibre), chitosan, flavouring agents (essential oils, powders and the like): mint (peppermint, spearmint, sweet mint), badian anethole, vanilla, sage, liver, sodium glutamate, fish meal, chicken, grapefruit, peach, lime or a mixture thereof.
The compositions according to the present invention may also contain at least a further active ingredient in combination with said at least a salt of SAMe, maintaining the high palatability of the compositions. Said further active ingredient is preferably selected from among vitamins, amino acids, glycosaminoglycans, flavolignans, hormones, natural substances of animal or vegetable origin, enzymes,-polysaccharides, probiotics or a mixture thereof.
In particular, said further active ingredient may be selected from among vitamins of group B such as, for example, vitamin B6, vitamin B12, vitamin B9 (folic acid), methylfolate, vitamin C; magnesium salts; taurine, tryptophan, reduced glutathione, n-acetylcysteine, tyrosine; hyaluronic acid, silymarin, silybin, theanine, melatonin, bromelain, hypericum, lipoic acid, lycopenes, bioflavonoids, rutin, valerian, glucosamine, chondroitin sulphate, chitosan, ursodeoxycholic acid, lactobacillus acidophilus, lactobacillus vulgaris, bifidum bacterium brevi, bifidum infantis, bifidum bacterium lactis, bifidum bacterium longum, lactobacillus bulgaricus, lactobacillus casei, lactobacillus plantarum, lactobacillus rhamnosus;
melissa, cinnamon, hawthorn, granadilla, fennel, dried garlic, onion, melaleuca, sweet orange, camomile, thyme (in form of essential oils, mother tinctures, retted glycerides or powders), betaine, aspartic acid, glutamine, phosphoserine, phosphatidylserine, choline, coenzyme Q10, dimethylglycine, hydroxymethylbutyrate, lactoferrin, methylsulfonylmethane, homotaurine, p-aminobenzoic acid (PABA), monacuspurpureus or a mixture thereof.
Said at least an additional active ingredient is contained in the composition of the invention in an amount ranging from 0.05% to 70%, preferably from 0.1 to 55%, with respect to the total weight of the composition.
Said amount varies depending on the characteristics of the selected additional active ingredient.
In particular, in case the additional active ingredient is one of the abovementioned vitamins of group B the dose according to the invention ranges from 0.00001 to 3%, preferably from 0.00005 to 1%, with respect to the total weight of the composition.
As mentioned above, administration of the composition according to the present invention guarantees an improved bioavailability of the drug, with respect to the compositions already available in the market; as a matter of fact, the administration of the invention allows reaching the plasma peak of the SAMe ion (maximum plasma concentration) within a period of time comprised between 1 and 2 hours from intake, preferably within about 1 and a half hours, with respect to a period of time of about 5 hours observed regarding a swallowable gastro-resistant tablet available in the market.
Said plasma peak of the invention corresponds to a plasma concentration value of the SAMe ion greater than 40-50% with respect to the base value, preferably equivalent to a value higher than 48% with respect to the base value, instead of the 1 % observed on a swallowable gastro-resistant tablet available in the market.
Thus, the present invention is also aimed at providing a method for obtaining the plasma peak of the SAMe ion within a period of time comprised between 1 and 2 hours from the intake, preferably within a period of time of about 1 and a half hours, characterized by the intake of the composition according to the present invention.
In particular, the method of the present invention determines a plasma concentration of the SAMe ion greater than 40-50% with respect to the base value, preferably greater than a value of about 48%, with respect to the base value.
The present invention is thus aimed at providing a method for increasing the plasma concentration of the SAMe ion characterized by administering the composition of the invention.
In particular, according to the method of the invention the value of the plasma concentration of the SAMe ion increases from 30 to 40% within a period of time preferably comprised between 20 and 40 minutes after administering the abovementioned composition. More preferably, the plasma concentration value of the SAMe ion increases by about 35% after about 30 minutes from the intake of the composition of the invention.
According to the method of the invention, the plasma peak of the SAMe ion (maximum plasma concentration) is attained within a period of time comprised between 1 and 2 hours, while the plasma concentration already increases considerably after a period of time comprised between 20 and 40 minutes from intake, thus guaranteeing the fast effectiveness.
Furthermore, the present invention refers to orosoluble and/or effervescent compositions containing at least a salt of SAMe combined with physiologically acceptable excipients used for treating, human or veterinarian, neuropsychiatric, osteoarticular or hepatic diseases and/or for treating disorders or discomforts deriving from the abovementioned diseases, in particular, diseases and/or disorders regarding the emotional sphere (depression syndromes in general, anxiety) and cognitive sphere (dementia), hepatic disorders both acute and chronic (alcoholic steatosis, acute and chronic hepatitis, alcoholic and post-viral cirrhosis, intrahepatic cholestasis) and degenerative skeletal-muscular diseases distinguished by mobility disorders (osteoarthrosis).
The abovementioned compositions for use in the treatment of human or veterinarian, neuropsychiatric, osteoarticular or hepatic diseases and/or disorders or discomforts deriving from the abovementioned diseases may also contain additional active ingredients. Said additional active ingredients being preferably selected from among vitamins, amino acids, glycosaminoglycans, flavolignans, hormones, natural substances of animal or vegetable origin, enzymes, polysaccharides, probiotics.
The compositions of the present invention may be prepared through a process comprising the following steps:
Scheme A (for orosoluble and/or effervescent tablets or granules and capsules):
1) Weighing the active components and excipients;
2) Mixing (mixer with rotating screw);
3) Compression;
4) Dry granulation of the obtained tablets;
5) Final compression or using the granules obtained in step 4 directly packaged in sachets or capsules.
Scheme B (for orosoluble tablets or granules and capsules 1) Weighing components except light magnesium oxide and at least a salt of SAMe;
2) Granulation by means of a slurry with a moistening mixture made up of an aqueous solution of a binding excipient;
3) Drying on a fluid bed until moisture below about 1% is obtained;
4) Adjusting the granules size by means of an oscillating granulator provided with a perforated stainless steel mesh (preferably with 1.5 mm diameter holes);
5) Mixing the granules + at least a salt of SAMe + light magnesium oxide +
flavouring agents;
Scheme B (for orosoluble tablets or granules and capsules 1) Weighing components except light magnesium oxide and at least a salt of SAMe;
2) Granulation by means of a slurry with a moistening mixture made up of an aqueous solution of a binding excipient;
3) Drying on a fluid bed until moisture below about 1% is obtained;
4) Adjusting the granules size by means of an oscillating granulator provided with a perforated stainless steel mesh (preferably with 1.5 mm diameter holes);
5) Mixing the granules + at least a salt of SAMe + light magnesium oxide +
flavouring agents;
6) Final compression or using the granules obtained in step 5 directly packaged in sachets or capsules.
Scheme C (for orosoluble tablets or granules and capsules):
1) Weighing all components;
2) Granulation by mixing with rendered vegetable fats;
3) Refrigeration and granulation of the mixture;
4) Adjusting the granules size by means of an oscillating granulator provided with a perforated stainless steel mesh (preferably with 1.5 mm diameter holes);
5) Final compression or using the granules obtained in step 4 directly packaged in sachets or capsules.
The process of the present invention is preferably performed maintaining the temperature between about 20 C and 30 C, more preferably at about 25 C, with relative humidity preferably not exceeding 28%.
According to the abovementioned process the finished product has relative humidity preferably below 3%, more preferably below 1.5%.
The following examples represent a detailed description of the compositions of the invention without limiting the contents thereof in any way whatsoever.
EXAMPLES
Example 1 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tosylate (para-toluenesulfonate) 200 mg (equivalent to 100 mg of the SAMe ion) (13.33%) Folic acid 0.15 mg (0.010 %) Vitamin B 12 0.001 mg (6.6* 10"5 %) Light magnesium oxide 40 mg (2.67 %) Stearic acid 90 mg (6 %) Glycerol behenate 7 mg (0.47 %) Magnesium stearate 10 mg (0.66 %) Mint flavour 3.53 mg (0.24%) Mixture of flavours: 0.3 mg (0.020 %) (Lime, Granadilla and Hawthorn) Silica gel 4.53 mg (0.3 %) Xylitol 350 mg (23.33 %) Mannitol 793 mg (52.86 %) Sucralose 1.45 mg (0.1 %) Neohesperidin 0.16 mg (0.010 %) TOTAL weight of the tablet 1500.12 mg Orosoluble tablets are preferably made having a diameter of 19 mm and weighing about 1.50 g Example 2 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tosylate 233 mg (equivalent to 119.76 mg of the SAMe ion) (10.53 %) Light magnesium oxide 44 mg (2 %) Stearic acid 80 mg (3.6 %) Glycerol behenate 7 mg (0.3 %) Magnesium stearate 10 mg (0.45 %) Mint flavour 3.53 mg (0.16 %) Essential Melissa oil 0.1 mg (0.007 %) Anethole 0.056 mg (0.005 %) Silica gel 4.53 mg (0.2 %) Inositol 908 mg (41.08 %) Mannitol 470.21 mg (21.25 %) Xylitol 450 mg (20.34 %) Sucralose 1.6 mg (0.07 %) Neohesperidin 0.18 mg (0.008 %) TOTAL tablet weight 2212.21 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2.2 g Example 3 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tos. lam to (para-toluenesulfonate) 420 mg (equivalent to 200 mg of the SAMe ion) (17.87 %) Light magnesium oxide 150 mg (6.38 %) Stearic acid 160 mg (6.8 %) Glycerol behenate 13 mg (0.55 %) Magnesium stearate 20 mg (0.85 %) Xylitol 859.57 mg (36.57 %) Man itol 700 mg (29.78 %) Sucralose 4.5 mg (0.19 %) Neohesperidine 0.3 mg (0.01 %) Orange flavour 14.63 mg (0.62 %) Silica gel 8 mg (0.34 %) TOTAL tablet weight 2350.00 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2.4 g Example 4 Effervescent orosoluble tablet based on SAMe tosylate (Para-toluenesulfonate) SAMe tosylate (para-toluenesulfonate) 233 mg (equivalent to 119.762 mg of the SAMe ion) (10.30 %) Light magnesium oxide 20.5 mg (0.9 %) L-leucine 24 mg (1.06 %) Glycerol behenate 4 mg (0.18 %) Magnesium stearate 1 mg (0.04 %) Grapefruit flavour powder 50 mg (2.21 %) Inositol 800 mg (35.36 %) Sucralose 10 mg (0.44 %) Anhydrous disodium carbonate 400 mg (17.68 %) Citric acid 250 mg (11.05 %) Adipic acid 250 mg (11.05 %) Sodium carbonate 200 mg (8.85 %) Silica gel 20 mg (0.88 %) TOTAL tablet weight 2262.50 mg Tablets are preferably made having a diameter of 22 mm and weighing about 2.2 g Example 5 Orosoluble tablet based on SAMe tos ly ate (para-toluenesulfonate) (veterinary use) SAMe tosylate (para-toluenesulfonate) 233 mg (equivalent to 119.762 mg of the SAMe ion) (9.19 %) Light magnesium oxide 38.5 mg (1.52 %) Glycerol behenate 7 mg (0.27 %) Stearic acid 80 mg (3.15 %) Liver flavour 2 mg (0.08 %) Yeast flavour 1 mg (0.04 %) Silica gel 20 mg (0.79 %) Dry liver 500 mg (19.72 %) Dry yeast 1200 mg ( 47.32 %) Glucosamine sulphate 250 mg (9.87 %) Monosodium glutamate 50 mg (1.97 %) Sodium chloride 20 mg (0.79 %) Xylitol 134 mg (5.28 %) Neohesperidine 0.2 mg (0.01 %) TOTAL tablet weight 2535.70 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2.5 g.
Example 6 Orosoluble tablet based on SAMe butanedisulfonate (veterinary use) SAMe butanedisulfonate 233 mg (equivalent to 119.762 mg of the SAMe ion) (10.19 %) Light magnesium oxide 38.5 mg (1.68 %) Glycerol behenate 7 mg (0.31 %) Stearic acid 80 mg (3.5 %) Liver flavour 2 mg (0.09 %) Yeast flavour 1 mg (0.04 %) Silica gel 20 mg (0.87 %) Dry liver 500 mg (21.88 %) Dry yeast 1200 mg (52.5 %) Monosodium glutamate 50 mg (2.19 %) Sodium chloride 20 mg (0.88 %) Xylitol 134 mg (5.86 %) Neohesperidine 0.2 mg (0.01 %) TOTAL tablet weight 2285.70 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2.25 g Example 7 Orosoluble tablet based on SAMe phytate SAMe phytate 215 mg (equivalent to 113.10 mg of the SAMe ion) (14.41 %) Silymarin 100 mg (6.7 %) Reduced glutathione 25 mg (1.68 %) Ursodeoxycholic acid 150 mg (10.05 %) Light magnesium oxide 42 mg (2.82 %) Palm oil 25 mg (1.68 %) Maltodextrine 200 mg (13.52 %) Mannitol 700 mg (46.94 %) Magnesium stearate 15 mg (1 %) Dextrose 5 mg (0.33 %) Spray dried malt 2,5 mg (0.17 %) Mixture of flavours 6 mg (0.4 %) (thyme, mint, spearmint, vanilla) Silica gel 4 mg (0.20 %) Sucralose 2 mg (0.10 %) TOTAL tablet weight 1491.50 mg Orosoluble tablets are preferably made having a diameter of 19 mm and weighing about 1.5 g Example 8 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tosylate (para-toluenesulfonate) 243 mg (equivalent to 121.5 mg of the SAMe ion) (11.61 %) Valerian 150 mg (7.17 %) Hypericum 7 mg (0.33 %) Tryptophan 100 mg (4.78 %) Light magnesium oxide 33 mg (1.58 %) Glycerol behenate 85 mg (4.06 %) Magnesium stearate 11 mg (0.52 %) Xylitol 500 mg (23.90 %) Mannitol 950 mg (45.40 %) Silica gel 3.7 mg (0.18 %) Acesulfame K 1.2 mg (0.05 %) Cyclamate 0.9 mg (0.04 %) Mixture of flavours: 4.5 mg (0.21 %) (Peppermint, fennel and cinnamon) Silica gel 3.5 mg (0.17 %) TOTAL tablet weight 2092.80 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2 g Example 9 Effervescent orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) and SAMe butanedisulfonate SAMe tos ly ate (para-toluenesulfonate) 90 mg (equivalent to 45 mg of the SAMe ion) (7.37 /x) SAMe butanedisulfonate 90 mg (equivalent to 45 mg of the SAMe ion) (7.37%) N-acetylcysteine 50 mg (4.09 %) Vitamin C 60 mg (4.91 %) Bioflavonoids 150 mg (12.29 %) Light magnesium oxide 29 mg (2.37 %) Potassium bicarbonate 400 mg (32.77 %) Tartaric acid 230 mg (18.85 %) Citric acid 50 mg (4.1 %) Leucine 40 mg (3.28 %) Glycerol behenate 6 mg (0.49 %) Magnesium stearate 7 mg (0.57 %) Sodium aspartate 3,5 mg (0.28 %) Maltitol 5 mg (0.42 %) Mixture of flavours: 5 mg (0.42 %) (sweet mint, sage) Silica gel 5 mg (0.42 %) TOTAL tablet weight 1220.50 mg Tablets are preferably made having a diameter 19 mm and weighing about 1.2 g Example 10 Orosoluble tablet based on SAMe butanedisulfonate SAMe butanedisulfonate 243 mg (equivalent to 127.8 mg of the SAMe ion) (14.38 %) Lactobacillus acidophilus (150 mid) 10 mg (0.59 %) Bifidum bacterium longum (100 mid) 20 mg (1.18 %) Sodium citrate 100 mg (5.91 %) Stearic acid 85 mg (5.22 %) Maize starch 50 mg (2.95 %) Magnesium stearate 14 mg (0.93 %) Silica gel 4.3 mg (0.25 %) Inulin 400 mg (23.65 %) Mannitol 300 mg (17.74 %) Sucrose 300 mg (17.74 %) Glycine 151 mg (8.99 %) Mixture of flavours: 3 mg (0.18 %) (melissa, granadilla and hawthorn) Silica gel 4 mg (0.23 %) Acesulfame K 1 mg (0.06 %) TOTAL tablet weight 1691.30 mg Orosoluble tablets are preferably made having a diameter of 19 mm and weighing about 1.6g Example 11 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) (sublingual) SAMe tosvlate (para-toluenesulfonate) mg (equivalent to 30.84 mg of the SAMe ion) (24.83 %) Melatonin 1 mg (0.42 %) Light magnesium oxide 4.8 mg (1.99 %) Glycerol behenate 19 mg (7.86 %) Magnesium stearate 2.5 mg (1.03 %) Xylitol 95 mg (39.32 %) Hydroxypropylcellulose 55 mg (22.77 %) Sucralose 0.5 mg (0.21 %) Mixture of flavours: 1.8 mg (0.74 %) (sweet orange oil and cinnamon) Silica gel 2 mg (0.83 %) TOTAL tablet weight 241.60 mg Sublingual tablets are preferably made weighing 0.24 g Example 12 Effervescent granules based on SAMe tosylate (para-toluenesulfonate) SAMe tos ly ate (para-toluenesulfonate) mg (equivalent to 80 mg of the SAMe ion) (13.20 %) Glucosamine 100 mg (8.25 %) Chondroitin sulphate 100 mg (8.25 %) Hyaluronic acid 5 mg (0.41 %) Light magnesium oxide 29 mg (2.2 %) Potassium bicarbonate 400 mg (33.00 %) Tartaric acid 230 mg (18.98 %) Citric acid 150 mg (12.37 %) Magnesium stearate 4 mg (0.33 %) Aspartame 4 mg (0.33 %) Xylitol 20 mg (1.76 %) Mixture of flavours: 5 mg (0.41 %) (granadilla, hawthorn and chamomile) Silica gel 5 mg (0.41 %) TOTAL weight 1212.00 mg Sachets are preferably made weighing about 1.2 g Example 13 Slightly effervescent orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tosylate (para-toluenesulfonate) 400 mg (equivalent to 200 mg of the SAMe ion) (32.24%) N-acetylcysteine 50 mg (4.03 %) Vitamin C 60 mg (4.83 %) Bioflavonoids 150 mg (12.09 %) Light magnesium oxide 29 mg (2.34 %) Potassium bicarbonate 200 mg (16.12 %) Tartaric acid 230 mg (18.54 %) Citric acid 50 mg (4Ø3 %) Leucine 40 mg (3.22 %) Glycerol behenate 6 mg (0.48 %) Magnesium stearate 7 mg (0.56 %) Sodium aspartate 3.5 mg (0.28 %) Citrus extract 5 mg (0.4 %) Mixture of flavours: 5 mg (0.4 %) (bitter orange) Silica gel 5 mg (0.4 %) TOTAL tablet weight 1240.50 mg Tablets are preferably made having a diameter 19 mm and weighing about 1.2 g EXPERIMENTAL PART
Using the formulation in the orosoluble tablet containing SAMe tosylate (para-toluenesulfonate) of example 2 (Quietosan =) a comparative trial was carried out to evaluate the bioavailability thereof compared to a composition formulated in swallowable gastro-resistant tablets available in the market (Samir(V ^).
For such purpose, six subjects from both genders, healthy volunteers, took under fasting, in a randomised manner and crossover pattern (i.e. a pattern according to which all patients take both treatments one after the other) 119.76 mg of the SAMe ion formulated according to the invention (formula example 2) and 200 mg of the SAMe ion in the swallowable gastro-resistant tablet available in the market (Samir(T).
The results obtained were normalised to take into account the concentration difference of the two pharmaceutical forms.
The plasma bioavailability, expressed as AUC, of the formulation in orosoluble tablets of SAMe tosylate according to the invention was considerably higher, averagely from about 150% to about 200% higher, with respect to the swallowable gastro-resistant one.
The concentration peak time was about one hour, one and a half hours (plasma bioavailability started increasing immediately after intake) for the orosoluble tablet of the invention and about 5 hours for the swallowable gastro-resistant one (Figure 1).
Furthermore as shown in Figure 1, plasma concentration after one hour - one and a half hours from the intake of the orosoluble tablet of the invention was about 48% higher than the base value, while the plasma bioavailability after one hour -one and a half hours from the intake of the swallowable gastro-resistant tablet is about I% higher with respect to the base value.
In addition, considering the plasma concentration of SAMe tosylate after 12 hours from intake of the tablet of the invention, as shown in Figure 2, it is about 30%
higher than the base value, while the plasma concentration of SAMe tosylate after 12 hours from the intake of the swallowable gastro-resistant tablet is about 11%
higher with respect to the base value.
Analogously, a trial was carried out on two healthy volunteers with respect to the orosoluble and effervescent composition of example 2 of the present invention which showed an intermediate pharmacokinetic behaviour between the orosoluble form tablets of the invention and the swallowable gastro-resistant one available in the market.
The orosoluble and effervescent composition revealed an AUC about 30-40%
higher with respect to the swallowable gastro-resistant form and a time of about 1-2 hours.
Thus, the advantage deriving from the compositions based on at least a salt of SAMe in orosoluble and/or effervescent form with high palatability according to the present invention is observable from the data indicated above.
Scheme C (for orosoluble tablets or granules and capsules):
1) Weighing all components;
2) Granulation by mixing with rendered vegetable fats;
3) Refrigeration and granulation of the mixture;
4) Adjusting the granules size by means of an oscillating granulator provided with a perforated stainless steel mesh (preferably with 1.5 mm diameter holes);
5) Final compression or using the granules obtained in step 4 directly packaged in sachets or capsules.
The process of the present invention is preferably performed maintaining the temperature between about 20 C and 30 C, more preferably at about 25 C, with relative humidity preferably not exceeding 28%.
According to the abovementioned process the finished product has relative humidity preferably below 3%, more preferably below 1.5%.
The following examples represent a detailed description of the compositions of the invention without limiting the contents thereof in any way whatsoever.
EXAMPLES
Example 1 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tosylate (para-toluenesulfonate) 200 mg (equivalent to 100 mg of the SAMe ion) (13.33%) Folic acid 0.15 mg (0.010 %) Vitamin B 12 0.001 mg (6.6* 10"5 %) Light magnesium oxide 40 mg (2.67 %) Stearic acid 90 mg (6 %) Glycerol behenate 7 mg (0.47 %) Magnesium stearate 10 mg (0.66 %) Mint flavour 3.53 mg (0.24%) Mixture of flavours: 0.3 mg (0.020 %) (Lime, Granadilla and Hawthorn) Silica gel 4.53 mg (0.3 %) Xylitol 350 mg (23.33 %) Mannitol 793 mg (52.86 %) Sucralose 1.45 mg (0.1 %) Neohesperidin 0.16 mg (0.010 %) TOTAL weight of the tablet 1500.12 mg Orosoluble tablets are preferably made having a diameter of 19 mm and weighing about 1.50 g Example 2 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tosylate 233 mg (equivalent to 119.76 mg of the SAMe ion) (10.53 %) Light magnesium oxide 44 mg (2 %) Stearic acid 80 mg (3.6 %) Glycerol behenate 7 mg (0.3 %) Magnesium stearate 10 mg (0.45 %) Mint flavour 3.53 mg (0.16 %) Essential Melissa oil 0.1 mg (0.007 %) Anethole 0.056 mg (0.005 %) Silica gel 4.53 mg (0.2 %) Inositol 908 mg (41.08 %) Mannitol 470.21 mg (21.25 %) Xylitol 450 mg (20.34 %) Sucralose 1.6 mg (0.07 %) Neohesperidin 0.18 mg (0.008 %) TOTAL tablet weight 2212.21 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2.2 g Example 3 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tos. lam to (para-toluenesulfonate) 420 mg (equivalent to 200 mg of the SAMe ion) (17.87 %) Light magnesium oxide 150 mg (6.38 %) Stearic acid 160 mg (6.8 %) Glycerol behenate 13 mg (0.55 %) Magnesium stearate 20 mg (0.85 %) Xylitol 859.57 mg (36.57 %) Man itol 700 mg (29.78 %) Sucralose 4.5 mg (0.19 %) Neohesperidine 0.3 mg (0.01 %) Orange flavour 14.63 mg (0.62 %) Silica gel 8 mg (0.34 %) TOTAL tablet weight 2350.00 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2.4 g Example 4 Effervescent orosoluble tablet based on SAMe tosylate (Para-toluenesulfonate) SAMe tosylate (para-toluenesulfonate) 233 mg (equivalent to 119.762 mg of the SAMe ion) (10.30 %) Light magnesium oxide 20.5 mg (0.9 %) L-leucine 24 mg (1.06 %) Glycerol behenate 4 mg (0.18 %) Magnesium stearate 1 mg (0.04 %) Grapefruit flavour powder 50 mg (2.21 %) Inositol 800 mg (35.36 %) Sucralose 10 mg (0.44 %) Anhydrous disodium carbonate 400 mg (17.68 %) Citric acid 250 mg (11.05 %) Adipic acid 250 mg (11.05 %) Sodium carbonate 200 mg (8.85 %) Silica gel 20 mg (0.88 %) TOTAL tablet weight 2262.50 mg Tablets are preferably made having a diameter of 22 mm and weighing about 2.2 g Example 5 Orosoluble tablet based on SAMe tos ly ate (para-toluenesulfonate) (veterinary use) SAMe tosylate (para-toluenesulfonate) 233 mg (equivalent to 119.762 mg of the SAMe ion) (9.19 %) Light magnesium oxide 38.5 mg (1.52 %) Glycerol behenate 7 mg (0.27 %) Stearic acid 80 mg (3.15 %) Liver flavour 2 mg (0.08 %) Yeast flavour 1 mg (0.04 %) Silica gel 20 mg (0.79 %) Dry liver 500 mg (19.72 %) Dry yeast 1200 mg ( 47.32 %) Glucosamine sulphate 250 mg (9.87 %) Monosodium glutamate 50 mg (1.97 %) Sodium chloride 20 mg (0.79 %) Xylitol 134 mg (5.28 %) Neohesperidine 0.2 mg (0.01 %) TOTAL tablet weight 2535.70 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2.5 g.
Example 6 Orosoluble tablet based on SAMe butanedisulfonate (veterinary use) SAMe butanedisulfonate 233 mg (equivalent to 119.762 mg of the SAMe ion) (10.19 %) Light magnesium oxide 38.5 mg (1.68 %) Glycerol behenate 7 mg (0.31 %) Stearic acid 80 mg (3.5 %) Liver flavour 2 mg (0.09 %) Yeast flavour 1 mg (0.04 %) Silica gel 20 mg (0.87 %) Dry liver 500 mg (21.88 %) Dry yeast 1200 mg (52.5 %) Monosodium glutamate 50 mg (2.19 %) Sodium chloride 20 mg (0.88 %) Xylitol 134 mg (5.86 %) Neohesperidine 0.2 mg (0.01 %) TOTAL tablet weight 2285.70 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2.25 g Example 7 Orosoluble tablet based on SAMe phytate SAMe phytate 215 mg (equivalent to 113.10 mg of the SAMe ion) (14.41 %) Silymarin 100 mg (6.7 %) Reduced glutathione 25 mg (1.68 %) Ursodeoxycholic acid 150 mg (10.05 %) Light magnesium oxide 42 mg (2.82 %) Palm oil 25 mg (1.68 %) Maltodextrine 200 mg (13.52 %) Mannitol 700 mg (46.94 %) Magnesium stearate 15 mg (1 %) Dextrose 5 mg (0.33 %) Spray dried malt 2,5 mg (0.17 %) Mixture of flavours 6 mg (0.4 %) (thyme, mint, spearmint, vanilla) Silica gel 4 mg (0.20 %) Sucralose 2 mg (0.10 %) TOTAL tablet weight 1491.50 mg Orosoluble tablets are preferably made having a diameter of 19 mm and weighing about 1.5 g Example 8 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tosylate (para-toluenesulfonate) 243 mg (equivalent to 121.5 mg of the SAMe ion) (11.61 %) Valerian 150 mg (7.17 %) Hypericum 7 mg (0.33 %) Tryptophan 100 mg (4.78 %) Light magnesium oxide 33 mg (1.58 %) Glycerol behenate 85 mg (4.06 %) Magnesium stearate 11 mg (0.52 %) Xylitol 500 mg (23.90 %) Mannitol 950 mg (45.40 %) Silica gel 3.7 mg (0.18 %) Acesulfame K 1.2 mg (0.05 %) Cyclamate 0.9 mg (0.04 %) Mixture of flavours: 4.5 mg (0.21 %) (Peppermint, fennel and cinnamon) Silica gel 3.5 mg (0.17 %) TOTAL tablet weight 2092.80 mg Orosoluble tablets are preferably made having a diameter of 22 mm and weighing about 2 g Example 9 Effervescent orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) and SAMe butanedisulfonate SAMe tos ly ate (para-toluenesulfonate) 90 mg (equivalent to 45 mg of the SAMe ion) (7.37 /x) SAMe butanedisulfonate 90 mg (equivalent to 45 mg of the SAMe ion) (7.37%) N-acetylcysteine 50 mg (4.09 %) Vitamin C 60 mg (4.91 %) Bioflavonoids 150 mg (12.29 %) Light magnesium oxide 29 mg (2.37 %) Potassium bicarbonate 400 mg (32.77 %) Tartaric acid 230 mg (18.85 %) Citric acid 50 mg (4.1 %) Leucine 40 mg (3.28 %) Glycerol behenate 6 mg (0.49 %) Magnesium stearate 7 mg (0.57 %) Sodium aspartate 3,5 mg (0.28 %) Maltitol 5 mg (0.42 %) Mixture of flavours: 5 mg (0.42 %) (sweet mint, sage) Silica gel 5 mg (0.42 %) TOTAL tablet weight 1220.50 mg Tablets are preferably made having a diameter 19 mm and weighing about 1.2 g Example 10 Orosoluble tablet based on SAMe butanedisulfonate SAMe butanedisulfonate 243 mg (equivalent to 127.8 mg of the SAMe ion) (14.38 %) Lactobacillus acidophilus (150 mid) 10 mg (0.59 %) Bifidum bacterium longum (100 mid) 20 mg (1.18 %) Sodium citrate 100 mg (5.91 %) Stearic acid 85 mg (5.22 %) Maize starch 50 mg (2.95 %) Magnesium stearate 14 mg (0.93 %) Silica gel 4.3 mg (0.25 %) Inulin 400 mg (23.65 %) Mannitol 300 mg (17.74 %) Sucrose 300 mg (17.74 %) Glycine 151 mg (8.99 %) Mixture of flavours: 3 mg (0.18 %) (melissa, granadilla and hawthorn) Silica gel 4 mg (0.23 %) Acesulfame K 1 mg (0.06 %) TOTAL tablet weight 1691.30 mg Orosoluble tablets are preferably made having a diameter of 19 mm and weighing about 1.6g Example 11 Orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) (sublingual) SAMe tosvlate (para-toluenesulfonate) mg (equivalent to 30.84 mg of the SAMe ion) (24.83 %) Melatonin 1 mg (0.42 %) Light magnesium oxide 4.8 mg (1.99 %) Glycerol behenate 19 mg (7.86 %) Magnesium stearate 2.5 mg (1.03 %) Xylitol 95 mg (39.32 %) Hydroxypropylcellulose 55 mg (22.77 %) Sucralose 0.5 mg (0.21 %) Mixture of flavours: 1.8 mg (0.74 %) (sweet orange oil and cinnamon) Silica gel 2 mg (0.83 %) TOTAL tablet weight 241.60 mg Sublingual tablets are preferably made weighing 0.24 g Example 12 Effervescent granules based on SAMe tosylate (para-toluenesulfonate) SAMe tos ly ate (para-toluenesulfonate) mg (equivalent to 80 mg of the SAMe ion) (13.20 %) Glucosamine 100 mg (8.25 %) Chondroitin sulphate 100 mg (8.25 %) Hyaluronic acid 5 mg (0.41 %) Light magnesium oxide 29 mg (2.2 %) Potassium bicarbonate 400 mg (33.00 %) Tartaric acid 230 mg (18.98 %) Citric acid 150 mg (12.37 %) Magnesium stearate 4 mg (0.33 %) Aspartame 4 mg (0.33 %) Xylitol 20 mg (1.76 %) Mixture of flavours: 5 mg (0.41 %) (granadilla, hawthorn and chamomile) Silica gel 5 mg (0.41 %) TOTAL weight 1212.00 mg Sachets are preferably made weighing about 1.2 g Example 13 Slightly effervescent orosoluble tablet based on SAMe tosylate (para-toluenesulfonate) SAMe tosylate (para-toluenesulfonate) 400 mg (equivalent to 200 mg of the SAMe ion) (32.24%) N-acetylcysteine 50 mg (4.03 %) Vitamin C 60 mg (4.83 %) Bioflavonoids 150 mg (12.09 %) Light magnesium oxide 29 mg (2.34 %) Potassium bicarbonate 200 mg (16.12 %) Tartaric acid 230 mg (18.54 %) Citric acid 50 mg (4Ø3 %) Leucine 40 mg (3.22 %) Glycerol behenate 6 mg (0.48 %) Magnesium stearate 7 mg (0.56 %) Sodium aspartate 3.5 mg (0.28 %) Citrus extract 5 mg (0.4 %) Mixture of flavours: 5 mg (0.4 %) (bitter orange) Silica gel 5 mg (0.4 %) TOTAL tablet weight 1240.50 mg Tablets are preferably made having a diameter 19 mm and weighing about 1.2 g EXPERIMENTAL PART
Using the formulation in the orosoluble tablet containing SAMe tosylate (para-toluenesulfonate) of example 2 (Quietosan =) a comparative trial was carried out to evaluate the bioavailability thereof compared to a composition formulated in swallowable gastro-resistant tablets available in the market (Samir(V ^).
For such purpose, six subjects from both genders, healthy volunteers, took under fasting, in a randomised manner and crossover pattern (i.e. a pattern according to which all patients take both treatments one after the other) 119.76 mg of the SAMe ion formulated according to the invention (formula example 2) and 200 mg of the SAMe ion in the swallowable gastro-resistant tablet available in the market (Samir(T).
The results obtained were normalised to take into account the concentration difference of the two pharmaceutical forms.
The plasma bioavailability, expressed as AUC, of the formulation in orosoluble tablets of SAMe tosylate according to the invention was considerably higher, averagely from about 150% to about 200% higher, with respect to the swallowable gastro-resistant one.
The concentration peak time was about one hour, one and a half hours (plasma bioavailability started increasing immediately after intake) for the orosoluble tablet of the invention and about 5 hours for the swallowable gastro-resistant one (Figure 1).
Furthermore as shown in Figure 1, plasma concentration after one hour - one and a half hours from the intake of the orosoluble tablet of the invention was about 48% higher than the base value, while the plasma bioavailability after one hour -one and a half hours from the intake of the swallowable gastro-resistant tablet is about I% higher with respect to the base value.
In addition, considering the plasma concentration of SAMe tosylate after 12 hours from intake of the tablet of the invention, as shown in Figure 2, it is about 30%
higher than the base value, while the plasma concentration of SAMe tosylate after 12 hours from the intake of the swallowable gastro-resistant tablet is about 11%
higher with respect to the base value.
Analogously, a trial was carried out on two healthy volunteers with respect to the orosoluble and effervescent composition of example 2 of the present invention which showed an intermediate pharmacokinetic behaviour between the orosoluble form tablets of the invention and the swallowable gastro-resistant one available in the market.
The orosoluble and effervescent composition revealed an AUC about 30-40%
higher with respect to the swallowable gastro-resistant form and a time of about 1-2 hours.
Thus, the advantage deriving from the compositions based on at least a salt of SAMe in orosoluble and/or effervescent form with high palatability according to the present invention is observable from the data indicated above.
Claims (11)
1. A pharmaceutical, dietary or nutraceutical composition containing a salt of S-adenosyl methionine, combined with a physiologically acceptable excipient, wherein said composition is in the form of an orosoluble tablet and said physiologically acceptable excipient comprises light magnesium oxide.
2. A composition according to claim 1, wherein said salt of S-adenosyl methionine is a tosylate (para-toluenesulfonate), a butanedisulfonate, a phytate or any mixture thereof
3. A composition according to claim 1 or 2, wherein said salt of S-adenosyl methionine is contained in an amount ranging from 5 to 70% by weight, with respect to the total weight of the composition.
4. A composition according to claim 3, wherein said salt of S-adenosyl methionine is contained in an amount ranging from 7 to 50% by weight, with respect to the total weight of the composition.
5. A composition according to any one of claims 1 to 4, comprising a further active ingredient.
6. A composition according to claim 5, wherein said further active ingredient is a vitamin, amino acid, glycosaminoglycan, flavolignan, hormone, natural substance of animal or vegetable origin, enzyme, polysaccharide, probiotic or any mixture thereof
7. A composition according to claim 5, wherein said further active ingredient is a vitamin of group B, methylfolate, vitamin C, magnesium salt, taurine, tryptophan, reduced glutathione, n-acetylcysteine, tyrosine, hyaluronic acid, silymarin, silybin, melatonin, 1-theanine, bromelain, hypericum, lipoic acid, lycopene, bioflavonoid, rutin, valerian, glucosamine, chondroitin sulphate, chitosan, ursodeoxycholic acid, lactobacillus acidophilus, lactobacillus vulgaris, bifidum bacterium brevi, bifidum infantis, bifidum bacterium lactis, bifidum bacterium longum, lactobacillus bulgaricus, lactobacillus casei, lactobacillus plantarum, lactobacillus rhamnosus, melissa, cinnamon, hawthorn, granadilla, fennel, dried garlic, onion, melaleuca, sweet orange, camomile, thyme, betaine, phosphoserine, phosphatidylserine, aspartic acid, glutamine, choline, coenzyme Q10, dimethylglycine, hydroxyethylbutyrate, lactoferrin, methylsulfonylmethane, homotaurine, p-aminobenzoic acid (PABA), monacus purpureus or any mixture thereof
8. A composition according to any one of claims 1 to 7, wherein the composition has high palatability.
9. A composition according to any one of claims 1 to 8 for use in the treatment of a neuropsychiatric, osteoarticular or hepatic disease.
10. A composition according to claim 9, for use in the treatment of a depression syndrome, anxiety, dementia, alcoholic steatosis, acute hepatitis, chronic hepatitis, alcoholic cirrhosis, post-viral cirrhosis, intrahepatic cholestasis or a degenerative skeletal-muscular disease with a mobility disorder.
11. A composition according to claim 9 or 10 for use with human or in veterinary treatment.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2009A000162A IT1393331B1 (en) | 2009-02-09 | 2009-02-09 | ORO-SOLUBLE AND / OR EFFERVESCENT COMPOSITIONS CONTAINING AT LEAST A SALT OF S-ADENOSILMETIONINE (SAME) |
ITMI2009A000162 | 2009-02-09 | ||
US21955309P | 2009-06-23 | 2009-06-23 | |
US61/219,553 | 2009-06-23 | ||
PCT/IB2010/050087 WO2010089674A1 (en) | 2009-02-09 | 2010-01-11 | Orosoluble and/or effervescent compositions containing at least a salt of s- adenosyl methionine (same) |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2752009A1 CA2752009A1 (en) | 2010-08-12 |
CA2752009C true CA2752009C (en) | 2016-09-27 |
Family
ID=40995758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2752009A Active CA2752009C (en) | 2009-02-09 | 2010-01-11 | Orosoluble and/or effervescent compositions containing at least a salt of s-adenosyl methionine (same) |
Country Status (13)
Country | Link |
---|---|
US (1) | US10149821B2 (en) |
EP (1) | EP2393475B1 (en) |
AU (1) | AU2010212042A1 (en) |
BR (1) | BRPI1008213A2 (en) |
CA (1) | CA2752009C (en) |
DK (1) | DK2393475T3 (en) |
ES (1) | ES2539310T3 (en) |
IL (1) | IL213817A0 (en) |
IT (1) | IT1393331B1 (en) |
PL (1) | PL2393475T3 (en) |
PT (1) | PT2393475E (en) |
RU (1) | RU2524645C2 (en) |
WO (1) | WO2010089674A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2963239B1 (en) * | 2010-08-02 | 2013-03-08 | Vetalis | SOLAR EFFERVESCENT GALENIC FORMS FOR ANIMALS |
CN103841977B (en) * | 2011-08-12 | 2016-04-20 | 三菱瓦斯化学株式会社 | The compositions containing SAM of excellent storage stability |
US8877259B2 (en) | 2012-02-09 | 2014-11-04 | Mary Kay Inc. | Cosmetic formulation |
CN104418928B (en) * | 2013-08-27 | 2017-03-29 | 上海医药工业研究院 | A kind of preparation method of 1,4 fourth disulfonic acid ademetionine |
US9351921B1 (en) * | 2013-09-10 | 2016-05-31 | Spa De Soleil, Inc. | Microdermabrasion cream |
AT14825U1 (en) * | 2014-11-10 | 2016-07-15 | Eduard Rappold | Combination preparation containing ademetionin and vitamin B12 for the treatment and prevention of Alzheimer's disease type I (LOAD) |
ES2586632B1 (en) * | 2015-01-29 | 2017-09-05 | Wug Functional Gums, S.L | Composition for making chewing gum |
US9446100B2 (en) | 2015-02-13 | 2016-09-20 | Eastern Vision Limited | Dietary supplements and formulations |
CN104983026A (en) * | 2015-07-21 | 2015-10-21 | 上海海洋大学 | Haw effervescent tablet and preparation method thereof |
AU2016317046B2 (en) * | 2015-08-31 | 2022-03-10 | Nutramax Laboratories, Inc. | Compositions comprising magnolia, phellodendron, theanine and/or whey protein |
RU2611411C1 (en) * | 2016-01-11 | 2017-02-21 | Общество с ограниченной ответственностью "Трейдсервис" | Dispersible in water acetylcysteine tablet and method of manufacturing thereof |
ITUA20163269A1 (en) | 2016-05-09 | 2017-11-09 | Graal S R L | COMPOSITION OF OROBUCCIAL ABSORPTION FOR NEURO-PROTECTION |
IT201600080839A1 (en) * | 2016-08-01 | 2018-02-01 | Esserre Pharma Srl | Composition based on S-Adenosyl-L-Methionine and Melatonin for the treatment of eating disorders |
WO2019084540A1 (en) * | 2017-10-27 | 2019-05-02 | Zeta Biolongevity, Inc. | Compositions and methods for treating and preventing proteinuria and endothelial erosion |
IT201900015192A1 (en) | 2019-08-29 | 2021-03-01 | Graal S R L | Edible formulations based on active ingredients and arginine |
CN111172043B (en) * | 2020-01-14 | 2021-03-05 | 北京工商大学 | Fermentation method for improving synthesis of monascus pigment in monascus purpureus |
IT202000006127A1 (en) * | 2020-03-23 | 2021-09-23 | Fmc S R L | PHARMACEUTICAL, DIETETIC AND / OR FOOD FORMULATION BASED ON ADEMETHIONIN AND PROCESS OF REALIZATION OF THIS FORMULATION |
CN111297963B (en) * | 2020-04-10 | 2021-11-26 | 广东轻工职业技术学院 | Extract and composition for dispelling effects of alcohol and protecting liver as well as preparation method and application of extract and composition |
IT202000008482A1 (en) | 2020-04-21 | 2021-10-21 | Montefarmaco Otc S P A | ORAL COMPOSITION CONTAINING S-ADENOSYL METHIONINE (SAME) AND AT LEAST ONE PROBIOTIC AND ITS USE |
RU2749833C1 (en) * | 2020-08-11 | 2021-06-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет технологий и управления имени К.Г. Разумовского (ПКУ)" | Method for production of dietary vitaminized chocolate |
IT202000030914A1 (en) * | 2020-12-15 | 2022-06-15 | Mario Antonio Basile | SOLID PHARMACEUTICAL COMPOSITION OF ADEMETHIONINE AND CANNABIDIOL AND PROCESS FOR OBTAINING IT |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057672A (en) | 1973-05-29 | 1977-11-08 | The Goodyear Tire & Rubber Company | Compounded polyvinyl chloride |
IE39517B1 (en) * | 1973-06-27 | 1978-10-25 | Bioresearch Sas | Double salts of s-adenosyl-l-methhionine |
US4432975A (en) * | 1981-04-13 | 1984-02-21 | Icn Pharmaceuticals, Inc. | Process for introducing vitamin B-12 into the bloodstream |
IT1137640B (en) | 1981-08-24 | 1986-09-10 | Bioresearch Srl | STABLE SALTS OF S-ADENOSYLMETHIONINE, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS THAT INCLUDE THEM AS AN ACTIVE PRINCIPLE |
PT893992E (en) * | 1996-04-16 | 2004-06-30 | Novartis Consumer Health Sa | FORMS OF FAST DISINTEGRATION ORAL DOSAGE |
MX2007004495A (en) * | 2004-10-15 | 2007-05-10 | Pfizer Prod Inc | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline. |
US20060127506A1 (en) * | 2004-12-10 | 2006-06-15 | Hebert Rolland F | Compositions of S-adenosyl-L-methionine |
US20060198885A1 (en) * | 2005-02-22 | 2006-09-07 | Sun Pharmaceutical Industries Ltd. | Oral pharmaceutical composition |
ITRM20050344A1 (en) * | 2005-06-30 | 2007-01-01 | Luca Maria De | SALTS OR COMPLEXES OF METHYL-DONOR SUBSTANCES WITH PHYTIC ACID OR ITS DERIVATIVES AND RELATIVE METHOD OF SYNTHESIS. |
ITMI20060026A1 (en) * | 2006-01-10 | 2007-07-11 | Truffini & Regge Farmaceutici Srl | COMPOSITIONS FOR USE ON THE BASIS OF S-ADENOSYLMETHIONINE AND PROCESS FOR THEIR ACHIEVEMENT |
RU2313349C2 (en) * | 2006-01-16 | 2007-12-27 | Михаил Аркадьевич Шурдов | Method for treating oncological diseases |
ITMI20060629A1 (en) * | 2006-03-31 | 2007-10-01 | Daniele Giovannone | ORAL SOLID COMPOSITIONS BASED ON S-ADENOSYLMETIONINE AND PROCESS FOR THEIR ACHIEVEMENT |
US8597640B2 (en) * | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
EP2189154A1 (en) * | 2008-11-25 | 2010-05-26 | Gnosis S.p.A. | Effervescent tablets and mouth-soluble granulates of S-adenosyl methionine and process for the preparation thereof |
EP2193787A1 (en) | 2008-12-02 | 2010-06-09 | Giorgio Stramentinoli | Formulations for systemic buccal delivery comprising s-adenosylmethionine, their preparation and use |
-
2009
- 2009-02-09 IT ITMI2009A000162A patent/IT1393331B1/en active
-
2010
- 2010-01-11 PT PT107033557T patent/PT2393475E/en unknown
- 2010-01-11 BR BRPI1008213A patent/BRPI1008213A2/en not_active Application Discontinuation
- 2010-01-11 AU AU2010212042A patent/AU2010212042A1/en not_active Abandoned
- 2010-01-11 WO PCT/IB2010/050087 patent/WO2010089674A1/en active Application Filing
- 2010-01-11 PL PL10703355T patent/PL2393475T3/en unknown
- 2010-01-11 DK DK10703355.7T patent/DK2393475T3/en active
- 2010-01-11 CA CA2752009A patent/CA2752009C/en active Active
- 2010-01-11 ES ES10703355.7T patent/ES2539310T3/en active Active
- 2010-01-11 RU RU2011137151/15A patent/RU2524645C2/en active
- 2010-01-11 US US13/147,883 patent/US10149821B2/en active Active
- 2010-01-11 EP EP10703355.7A patent/EP2393475B1/en active Active
-
2011
- 2011-06-28 IL IL213817A patent/IL213817A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL2393475T3 (en) | 2015-08-31 |
US10149821B2 (en) | 2018-12-11 |
DK2393475T3 (en) | 2015-06-15 |
IT1393331B1 (en) | 2012-04-20 |
EP2393475B1 (en) | 2015-03-11 |
ITMI20090162A1 (en) | 2010-08-10 |
AU2010212042A1 (en) | 2011-07-21 |
ES2539310T3 (en) | 2015-06-29 |
US20110300081A1 (en) | 2011-12-08 |
AU2010212042A2 (en) | 2011-08-18 |
BRPI1008213A2 (en) | 2016-03-15 |
EP2393475A1 (en) | 2011-12-14 |
PT2393475E (en) | 2015-07-17 |
WO2010089674A1 (en) | 2010-08-12 |
IL213817A0 (en) | 2011-07-31 |
RU2524645C2 (en) | 2014-07-27 |
CA2752009A1 (en) | 2010-08-12 |
RU2011137151A (en) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2752009C (en) | Orosoluble and/or effervescent compositions containing at least a salt of s-adenosyl methionine (same) | |
KR101203186B1 (en) | Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof | |
EP1604659B1 (en) | Tablet containing water-absorbing amino acid | |
ES2635763T3 (en) | Nutritional Supplement Composition | |
ES2215079T3 (en) | GASTRORRESISTENT TABLETS FOR FOOD, DIETETIC AND THERAPEUTIC USE. | |
WO2012001977A1 (en) | Disintegrating composition and easily disintegrating compression molded article | |
JP2004242509A (en) | Food containing coenzyme q10 and amino acid | |
US11213505B2 (en) | Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof | |
EP2189154A1 (en) | Effervescent tablets and mouth-soluble granulates of S-adenosyl methionine and process for the preparation thereof | |
KR20220090615A (en) | Oral disintegrating tablet or sublingual tablet for health functional food | |
EP2370062A1 (en) | Formulations for systemic buccal delivery comprising s- adenosylmethionine, their preparation and use | |
JP4674955B2 (en) | Amino sugar-containing preparation | |
JP5527921B2 (en) | Oral solid composition concealing bitterness | |
JP2004002482A (en) | Pharmaceutical preparation containing aminosugar | |
JP2005281324A (en) | Amino sugar-containing preparation | |
EP4021508A1 (en) | Formulations comprising arginine and/or a pharmaceutically acceptable salt thereof and an acid active ingredient with a pka of 1 -5 | |
JP2011068614A (en) | Vitamin preparation | |
KR20140122017A (en) | Fast-disintegrating formulation containing entecavir or pharmaceutically acceptable salt thereof and preparation method thereof | |
TWI406679B (en) | Oral disintegrating tablet containing a high dosage of active ingredients | |
JP2017214432A (en) | Amino sugar-containing preparation | |
JP2016222726A (en) | Amino sugar-containing preparation | |
JP2014139254A (en) | Amino sugar-containing preparation | |
JP2010180254A (en) | Amino sugar-containing preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20150109 |